(NASDAQ: VKTX) reported completion of enrollment in its phase 3 VANQUISH-2 trial evaluating VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity treatment
Each option is reviewed individually, and recommendations depend on provider assessment, safety considerations, patient goals, and medication availability
This means there is no risk to hiring a qualified attorney to handle your case
Harnessing natures arsenal: targeting the tgf-/smad cascade with novel natural anti-fibrotic agents
Aim for blood pressure targets your doctor recommends, often below 130/80 Treat sleep apnea if diagnosed, as it affects blood flow to the optic nerve Maintain healthy cholesterol levels to reduce overall vascular risk Avoid smoking, which significantly worsens diabetic retinopathy Treatment Options for GLP-1-Related Eye Complications If you develop mild worsening of diabetic retinopathy during early GLP-1 treatment, we may recommend observation with more frequent monitoring rather than immediate intervention
Lifelong treatment may be needed when the body is unlikely to regain the ability to absorb enough vitamin B12, such as autoimmune gastritis or the major surgical causes identified by NICE